Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Jasper strengthens regulatory and clinical leadership and issues 243,000 inducement stock options to new employees with four-year vesting.
Rhea-AI Summary
Jasper Therapeutics (JSPR) appointed Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs, and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development following its merger with Kira Pharmaceuticals. The company said their regulatory and clinical expertise will support development of vensobafusp alfa (KP104), briquilimab and KP701 in immune-mediated diseases.
Pitt brings over 25 years of regulatory and medical affairs experience across industry and the U.S. Food and Drug Administration, including leadership roles at Aiolos Bio, NorthSea Therapeutics, Horizon Therapeutics, Viela Bio, AstraZeneca, PAREXEL and Novartis. Liu joins after more than a decade at Sanofi in research and development, pharmacovigilance and clinical development, with a focus on rare renal and metabolic diseases and late-stage trials.
On September 14, 2026, Jasper also granted three new employees stock options for an aggregate 243,000 shares at an exercise price of $0.6328 per share as material inducement grants under its 2022 Inducement Equity Incentive Plan. The options vest over four years, with 25% after one year and the remainder monthly, subject to continued service.
Positive
- Senior VP, Regulatory Affairs hired to support multiple immune-disease programs
- VP, Clinical Development appointed with late-stage rare disease trial experience
- Granted inducement options for 243,000 shares at $0.6328 per share
- Inducement options vest over 4 years, aligning new hires with long-term performance
Negative
- Inducement grants add potential dilution through 243,000 new option shares
Details
Market Reaction – JSPR
Following this news, JSPR has gained 5.24%, reflecting a notable positive market reaction. Our momentum scanner has triggered 9 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $0.60.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Inducement options
- 243,000 shares
- Granted to three new employees
- Option exercise price
- $0.6328 per share
- Each inducement option
- Vesting period
- 4 years
- Each inducement option
- Initial vesting
- 25%
- On the one-year employment anniversary
- Monthly vesting
- 1/48th
- Monthly after the one-year anniversary
Key Terms
pharmacovigilance medical
investigation new drug regulatory
new drug application regulatory
biologic license application regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs
Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development
REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory Affairs and Shiguang Liu, M.D., Ph.D. as Vice President, Clinical Development.
“We are excited to have Lisa and Shiguang join us at Jasper following our merger with Kira Pharmaceuticals,” said Jeet Mahal, President and Chief Executive Officer of Jasper. “Lisa’s experience in regulatory affairs at multiple biotech companies and the FDA, along with Shiguang’s expertise in clinical development in rare diseases in renal and metabolic disorders are key additions as we move forward with the development of vensobafusp alfa (KP104), briquilimab and KP701 across a number of immune diseases.”
Dr. Pitt brings over 25 years of experience in leading regulatory and medical affairs across both the industry and at the U.S. Food and Drug Administration (FDA). Most recently, she served as Vice President, Regulatory Affairs at Aiolos Bio prior to its acquisition by GlaxoSmithKline. Prior to that, she held regulatory affairs leadership roles at NorthSea Therapeutics, Horizon Therapeutics, and Viela Bio prior to its acquisition by Horizon Therapeutics. Dr. Pitt served as Senior Regulatory Health Project Manager at the FDA’s Center for Drug Evaluation & Research in the former Division of Gastroenterology and Inborn Errors Products, where she managed the review of Investigation New Drug (IND), New Drug Application (NDA), and Biologic License Application (BLA) submissions. Earlier in her career, she served in Regulatory Affairs roles at AstraZeneca, PAREXEL Consulting, and Novartis. She started her career in laboratory quality assurance roles at Alpharma and Cambridge Biotech. Dr. Pitt received her Pharm.D. from the University of Maryland School of Pharmacy, an M.S.J. from Seton Hall Law School, and a Bachelor degree in Biological Sciences from the University of Delaware, and completed a post-doctoral clinical pharmacy fellowship at Novartis.
Dr. Liu joins after spending over a decade of progressive leadership roles in research and development, pharmacovigilance, and clinical development at Sanofi. Most recently, he served as Clinical Lead and Senior Clinical Research Director with a focus on rare diseases in renal and metabolic disorders and leadership in late-stage clinical trials and regulatory submissions. Prior to joining the biopharmaceutical industry, Dr. Liu held several academic appointments, including Assistant Professor at The Kidney Institute at the University of Kansas Medical Center, research faculty at the Duke University School of Medicine, and Visiting Fellow at the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). Earlier in his career, he was an Associate Professor and Attending Physician at the First Affiliated Hospital of Zhengzhou University Medical School, where he also completed his residency training. Dr. Liu received his M.D. from Zhengzhou University Medical School as well as an M.S. in Medicine and a Ph.D. in Cell Biology from the Chinese Academy of Medical Sciences and Peking Union Medical College.
Material Inducement Grants
Jasper also announced that on September 14, 2026, it granted three new employees options to purchase an aggregate of 243,000 shares of voting common stock (the “Options”) as material inducements to each employee’s employment with Jasper in accordance with Nasdaq Listing Rule 5635(c)(4). The Options were granted pursuant to the Jasper Therapeutics, Inc. Amended and Restated 2022 Inducement Equity Incentive Plan, which was approved by the compensation committee of Jasper’s board of directors on March 14, 2022 and amended and restated on June 2, 2023. The exercise price of each Option is
About Jasper
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. Jasper is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
Contacts:
Alex Gray (investors)
Jasper Therapeutics
650-549-1454
agray@jaspertx.com
Argot Partners (investors and media)
kira@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which leadership roles are Lisa Pitt and Shiguang Liu assuming at Jasper Therapeutics?
Lisa Pitt has been appointed Senior Vice President, Regulatory Affairs, and Shiguang Liu has been appointed Vice President, Clinical Development.
What experience does Lisa Pitt bring to Jasper’s regulatory function?
Lisa Pitt has over 25 years of regulatory and medical affairs experience spanning industry and the U.S. Food and Drug Administration. She has held regulatory leadership roles at Aiolos Bio, NorthSea Therapeutics, Horizon Therapeutics, Viela Bio, AstraZeneca, PAREXEL Consulting and Novartis, and previously served as Senior Regulatory Health Project Manager at the FDA’s Center for Drug Evaluation & Research.
What is the background of Shiguang Liu in clinical development?
Shiguang Liu spent more than a decade at Sanofi in research and development, pharmacovigilance and clinical development, most recently as Clinical Lead and Senior Clinical Research Director focused on rare renal and metabolic diseases and late-stage trials and regulatory submissions. He also held academic roles at the University of Kansas Medical Center, Duke University School of Medicine, the NIH’s NIEHS, and Zhengzhou University Medical School.
How are the new Jasper inducement stock options structured and when do they vest?
On September 14, 2026, Jasper granted three new employees options to purchase an aggregate of 243,000 shares of voting common stock at an exercise price of $0.6328 per share under its Amended and Restated 2022 Inducement Equity Incentive Plan. Each option vests over four years, with 25% of the shares vesting on the one-year anniversary of the employee’s start date and 1/48 of the total shares vesting monthly thereafter, subject to continued service.
Under what framework were the inducement grants issued?
The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4), pursuant to Jasper’s Amended and Restated 2022 Inducement Equity Incentive Plan, which was approved on March 14, 2022 and amended and restated on June 2, 2023.